GlassScriptPhysician profile
Joseph A Cirello
NPI 1710144639
$9,478.45
in general payments reported to CMS, 2019-2025
40 companies · $924 in 2025
The $924 reported for 2025 was more than what 85% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,589 · 2020: $1,578 · 2021: $1,733 · 2022: $1,316 · 2023: $1,112 · 2024: $1,226 · 2025: $924.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,242 · Education: $20.76.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,242.28 |
| Education | $20.76 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,765.25 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $1,167.98 | 2019-2025 | Jardiance, Synjardy |
| Lilly USA, LLC | $1,101.54 | 2019-2025 | Jardiance, Mounjaro, Zepbound |
| Astrazeneca Pharmaceuticals LP | $1,005.09 | 2019-2025 | Farxiga, Breztri, Airsupra |
| Glaxosmithkline, LLC. | $849.96 | 2019-2024 | Trelegy Ellipta, Arexvy |
| Amgen INC. | $721.53 | 2019-2025 | Otezla, Repatha, Prolia |
| Radius Health, INC. | $350.64 | 2019-2025 | Tymlos |
| Sanofi-Aventis U.S. LLC | $277.37 | 2019-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $224.06 | 2019-2022 | |
| Teva Pharmaceuticals USA, INC. | $213.15 | 2019-2023 | Austedo, Austedo Xr |
| Abbvie INC. | $173.63 | 2021-2025 | Qulipta |
| Merck Sharp & Dohme LLC | $143.34 | 2019-2021 | |
| E.R. Squibb & Sons, L.L.C. | $141.00 | 2019-2024 | Eliquis |
| Pfizer INC. | $139.41 | 2019-2024 | |
| Esperion Therapeutics, INC. | $121.78 | 2021-2025 | Nexletol |
Show all 40 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Joseph Cirello listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.